Best Peptide for Cellular Energy: What SS-31 Studies Measure

Searching for the best peptide for cellular energy usually comes from a recognisable place: the sense that exercise takes more out of you than it once did, or that sleep has stopped translating neatly into stamina. The trouble is that “cellular energy” can mean several very different things. It can refer to ATP production in muscle, fatigue on a questionnaire, walking capacity, or simply how a person feels at 3 p.m.

SS-31, also called elamipretide, has more controlled human research than many compounds discussed in this space. But it cannot honestly be crowned “best.” One small trial measured a short-lived change in muscle ATP-production capacity; larger trials in people with inherited mitochondrial disease did not improve their main walking and fatigue outcomes. Those are related questions, not interchangeable answers.

Research Confidence

★★★★☆ Stronger than most peptide evidence because SS-31 has several randomized, placebo-controlled human trials, including one that directly measured muscle ATP production and a 218-person phase 3 trial. Confidence stops short of five stars because findings are mixed: the ATP signal was temporary, while the largest functional trial missed both main endpoints.

Study Snapshot

• Study type: randomized, double-blind, placebo-controlled trial
• Participants: 39 adults aged 60-85 years, 46% female
• Duration: one 2-hour intravenous infusion, assessed immediately and at day 7
• Measured: maximum ATP-production capacity in a hand muscle by phosphorus magnetic resonance spectroscopy
• Found: ATP-production capacity rose immediately versus placebo, but not at day 7; fatigue resistance did not significantly improve
• Funding: Stealth BioTherapeutics funded the study and collaborated on study design; authors reported prior consulting relationships

Why This Matters: “Cellular Energy” Is Not One Result

ATP is the molecule cells use to move energy around. Think of it less as a permanent battery charge and more as the spendable currency continually made and used by tissues. A muscle can show a laboratory change in ATP production without that change becoming easier stair climbing, less exhaustion after errands, or better exercise tolerance.

That distinction matters more in midlife and later life, when changes in muscle mass, sleep, illness, activity, and hormonal transition can all affect energy and recovery. A search for the best peptide for cellular energy deserves an answer that separates a machine-based measurement from a lived outcome.

For broader context on how compounds are evaluated before human findings become meaningful, see this guide to understanding research peptides. The question is not whether ATP matters. It plainly does. The question is whether changing a measurement changes daily function.

The Direct Measurement: A Brief ATP Signal in Older Muscle

The clearest SS-31 bioenergetics result came from a 2021 randomized, double-blind, placebo-controlled trial in 39 adults aged 60 to 85 selected for low muscle mitochondrial function. “Double-blind” means neither participants nor the study team assessing outcomes knew who received SS-31 or placebo at the time, helping reduce expectation effects.

After one intravenous infusion, the SS-31 group showed an immediate increase in ATPmax relative to placebo. ATPmax was measured in a hand muscle using phosphorus magnetic resonance spectroscopy, a non-invasive scan that tracks how quickly muscle restores a phosphorus-containing energy compound after activity. It is a direct physiological measure, not a self-report.

The important qualifier is timing. By day 7, the difference was no longer present. The same randomized trial also found no statistically significant improvement in resting mitochondrial coupling, a measure of how efficiently mitochondria turn fuel into usable energy, or in fatigue resistance during repeated muscle contractions.

That makes the finding interesting but narrow: a short-term laboratory signal in selected older adults, not evidence of sustained everyday energy.

The Functional Tests: Walking and Fatigue Did Not Line Up Neatly

People with primary mitochondrial myopathy have inherited disorders that impair mitochondrial function and can cause exercise intolerance and fatigue. Their studies are valuable tests of whether a mitochondrial-targeted compound can shift outcomes a person can actually notice, but they are not healthy-aging studies.

In a 2020 randomized, double-blind, placebo-controlled crossover trial, 30 adults with genetically confirmed primary mitochondrial myopathy received 40 mg daily subcutaneous elamipretide and placebo during separate four-week periods, with a four-week gap between them. A crossover design lets each participant serve as their own comparison. The main outcome, six-minute walking distance, did not reach conventional statistical significance: the estimated difference was 19.8 metres, with a range of plausible values spanning a small disadvantage to a larger benefit.

Several participant-reported fatigue measures favored SS-31 in that trial. But injection-site reactions occurred in 80% of participants and were mostly mild. A smaller 2018 randomized phase I and II trial in 36 adults likewise produced mixed efficacy results after five days: an adjusted analysis favored SS-31 for walking change at the highest tested infusion dose, while other efficacy and safety measures showed no significant differences.

The Largest Test: A Negative Phase 3 Trial Carries Weight

The decisive check on a promising early signal is a larger trial with outcomes set in advance. In the 2023 MMPOWER-3 phase 3 randomized, double-blind, placebo-controlled trial, 218 people with primary mitochondrial myopathy received 40 mg daily subcutaneous elamipretide or placebo for 24 weeks.

The two co-primary endpoints were six-minute walking distance and a disease-specific total fatigue score. A co-primary endpoint means both were designated as the trial’s main tests of success before results were known. SS-31 did not meet either one. The between-group walking difference was −3.2 metres, and the fatigue-score difference was −0.07; neither result was statistically significant. Most adverse events were mild to moderate.

This is why the phrase best peptide for cellular energy gets ahead of the evidence. A direct ATP measurement and a functional benefit are different claims. The former showed a temporary signal in one small study; the latter was not confirmed in the largest relevant trial.

SS-31 has FDA accelerated approval, under the brand name Forzinity, only to improve muscle strength in adults and children weighing at least 30 kg with Barth syndrome. That is not approval for healthy aging, fatigue, general mitochondrial function, or cellular energy.

What This Means For You: Ask Which Outcome Is Being Promised

If someone describes a compound as supporting “cellular energy,” a useful first question is: energy measured how? A muscle scan, a fatigue questionnaire, a walking test, and a wearable activity measure can each capture something real, but none substitutes for the others.

For a clinician conversation about persistent fatigue or declining exercise tolerance, it is reasonable to discuss more common contributors first, including sleep, medications, nutrition, mood, anaemia, thyroid disease, and changes in activity or muscle strength. The SS-31 evidence does not license an expectation of more day-to-day energy in generally healthy adults.

If your concern is maintaining function with age rather than treating a diagnosed mitochondrial disorder, the relevant outcomes are usually stamina, strength, mobility, and recovery—not a single laboratory number. Nuforme’s anti-aging research category provides related research context, but it does not change the limits of these trials.

What This Tells Us About Women Specifically: Menopausal Status Was Not Recorded

Women made up 46% of the 39-person older-adult ATP study and 64% of the 218-person MMPOWER-3 trial. That is better representation than an all-male study, but it does not answer a midlife-specific question.

Neither report recorded menopausal status or hormone therapy use, and neither published results separately for women and men. The research therefore cannot tell us whether perimenopause, menopause, or hormone treatment alters SS-31’s effect on ATP production, fatigue, walking capacity, or adverse events.

That gap matters because fatigue and muscle changes in midlife have many possible contributors. A mixed-sex average can hide different responses without proving that such differences exist.

Questions This Study Couldn't Answer: From ATPmax to Everyday Energy

• The 39-person older-adult trial could not show whether its immediate ATPmax change translated into better daily energy, function, or quality of life.
• It could not establish durability beyond seven days after a single infusion.
• The disease trials studied genetically confirmed primary mitochondrial myopathy, so their results do not directly apply to otherwise healthy people seeking healthy-aging support.
• Across the studies, sex-specific and menopause-specific effects were not reported.
• The 2021 ATP study was industry-funded, with funder involvement in study design and disclosed author consulting relationships. MMPOWER-3 also included numerous investigator relationships with the trial sponsor.

Future Research: Linking Muscle Scans to Daily Function

What would move confidence higher is a sufficiently large, preregistered placebo-controlled trial in a clearly defined population that measures both direct mitochondrial function and outcomes people can feel or do. It should follow participants longer, report withdrawals and adverse events transparently, and plan sex and menopausal-status analyses before results are examined. The key test is whether a bioenergetic signal persists and predicts meaningful function.

Research Use And Availability

SS-31 is supplied by Nuforme in Canada as a research material for laboratory research. It is designated for research use only and is not presented as a substitute for approved medical care or as a personal-use product. Nuforme’s research materials are accompanied by available product documentation and quality information; research supply should not be equated with FDA approval or eligibility for medical compounding.

Final Thoughts: The Honest Answer Is a More Useful One

SS-31 is among the better-studied compounds in human mitochondrial research, but that is not the same as being the best peptide for cellular energy. The most direct older-adult study found a temporary ATP-production signal without measured fatigue-resistance improvement. The largest disease-specific trial did not improve its main walking or fatigue outcomes. For now, the evidence supports careful interest in the research question—not a broad promise about how energetic a person will feel.